Actualités et vidéos - TXCELL

Sangamo Announces Completion Of TxCell Acquisition PR Newswire RICHMOND, Calif. and VALBONNE, France, Dec. 3, 2018 RICHMOND, Calif. and VALBONNE, France , Dec. 3, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. "The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development," said Sandy Macrae ,...

Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy PR Newswire RICHMOND, Calif. and VALBONNE, France, Oct. 1, 2018 RICHMOND, Calif. and VALBONNE, France , Oct. 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) today jointly announced the completion by Sangamo of the acquisition of ordinary shares...

Sangamo Therapeutics to Acquire TxCell The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development Initiation of First CAR-Treg Clinical Trial Expected in 2019 PR Newswire RICHMOND, Calif. and VALBONNE, France, July 23, 2018 RICHMOND, Calif. and VALBONNE, France , July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) announced today...

Edison Investment Research Limited Edison Investment Research Limited: Edison issues outlook on TxCell (TXCL) 22-Feb-2018 / 09:47 GMT/BST London, UK, 22 February 2018 Edison issues outlook on TxCell (TXCL) TxCell has disclosed that it has a viable manufacturing route for its novel CAR Treg products. This uses a stable but low-frequency Treg cell type. The TxCell methodology uses a robust design to give low inter-patient variability with potentially consistent therapeutic results. Regulatory...

TxCell offers a rare investment opportunity as it is the only company applying CAR-T technology to regulatory T-cells (Tregs) for autoimmune and inflammatory ......

...

...